| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Target: 24,25-Dihydroxy Vitamin D3 is involved in calcium metabolism pathways and alkaline phosphatase activity. It enhances the calcemic effect of calcitriol. The compound is a marker of calcitriol catabolism via the conversion of 1,25-dihydroxyvitamin D3 by 24-hydroxylase (CYP24A1). It is a physiologically active metabolite of vitamin D with roles in bone and mineral metabolism.
|
|---|---|
| ln Vitro |
24, 25-DiHydroxy VD3 (24R,25(OH)2D3) (0.002-202 nM), which has an EC50 of 4.9 nM and a maximal inhibition rate of 60%, reduces the increase in intracellular Ca2+ concentration in a dose-dependent manner. Enterocytes of Atlantic cod that are hermaphrodites [1].
In Vitro Activity: 24,25-Dihydroxy VD3 (24R,25(OH)2D3) (0.002-202 nM) reduces the increase in intracellular Ca2+ concentration in a dose-dependent manner with an EC50 of 4.9 nM and a maximal inhibition rate of 60% in enterocytes of Atlantic cod. The compound shows anticancer and anti-inflammatory activities. It inhibits some metabolic processes. |
| ln Vivo |
In Vivo Activity: 24,25-Dihydroxy Vitamin D3 has been studied in participants with chronic kidney disease, where lower serum concentrations correlated with decreased renal function and secondary hyperparathyroidism. 24,25(OH)2D3 appears to be a very appropriate metabolite for assessing vitamin D metabolism disorders in CKD because it represents the result of a feedback mechanism. It plays a role in calcium and phosphate homeostasis.
|
| Enzyme Assay |
In Vitro Enzyme/Receptor Binding Protocol: Vitamin D receptor binding assays typically use recombinant VDR protein or cell extracts. Radioligand binding with [3H]1,25(OH)2D3 is performed with varying concentrations of 24,25-Dihydroxy Vitamin D3 to determine relative binding affinity. Calcium flux assays in enterocytes measure the compound's effect on intracellular calcium using fluorescent indicators.
|
| Cell Assay |
In Vitro Cell-Based Assay Protocol: Enterocytes or other cell types are treated with 24,25-Dihydroxy Vitamin D3 at various concentrations (0.002-202 nM). Intracellular calcium concentrations are measured using fluorescent calcium indicators such as Fura-2. Cell proliferation, differentiation, and gene expression assays may also be performed. Anticancer and anti-inflammatory activities can be assessed in appropriate cell models.
|
| Animal Protocol |
In Vivo Animal Assay Protocol: Animal models of calcium metabolism disorders or kidney disease are used to study 24,25-Dihydroxy Vitamin D3. The compound is administered via appropriate routes, and serum calcium, phosphate, and vitamin D metabolite levels are measured. CKD models may be employed to assess the compound's role as a marker of calcitriol catabolism.
|
| ADME/Pharmacokinetics |
Pharmacokinetics: 24,25-Dihydroxy Vitamin D3 has molecular formula C27H44O3 and molecular weight 416.64. It is a naturally occurring vitamin D metabolite produced from calcitriol via CYP24A1. The compound has a relatively long half-life and circulates at higher concentrations than 1,25(OH)2D3. It serves as a marker of calcitriol catabolism.
|
| Toxicity/Toxicokinetics |
Toxicity: No significant toxicity is associated with 24,25-Dihydroxy Vitamin D3 at physiological concentrations. As an endogenous metabolite, it is generally well-tolerated. High doses may cause hypercalcemia similar to other vitamin D compounds. The compound is for research use only and is not approved for therapeutic applications.
|
| References | |
| Additional Infomation |
24,25-Dihydroxycholecalciferol is a vitamin D derivative derived from calcitriol via the conversion of 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1). 24,25-Dihydroxycholecalciferol is a marker of calcitriol catabolism because it is a major metabolite of calcitriol and its urinary levels are elevated in certain diseases, such as chronic kidney disease (CKD). It is a physiologically active metabolite of vitamin D. This compound participates in regulating calcium metabolism, alkaline phosphatase activity, and enhancing the calcium-promoting effect of calcitriol.
Additional Information: 24,25-Dihydroxy Vitamin D3 has CAS number 40013-87-4. It is also known as 24,25-dihydroxyvitamin D3, 24,25(OH)2D3, and DHVD3. The compound is a marker of calcitriol catabolism because it is a major metabolite of calcitriol and its urinary levels are elevated in certain diseases such as CKD. It is a physiologically active metabolite of vitamin D that participates in regulating calcium metabolism and alkaline phosphatase activity. For research use only. |
| Molecular Formula |
C27H44O3
|
|---|---|
| Molecular Weight |
416.63646
|
| Exact Mass |
416.329
|
| CAS # |
40013-87-4
|
| Related CAS # |
1173-13-3 (Previtamin D3); 56142-94-0 (24-Hydroxycalcitriol); 22350-41-0 (5,6-trans-Vitamin D3);67-97-0(vitamin D3); 32222-06-3 (Calcitriol, 1,25-Dihydroxyvitamin D3); 19356-17-3 (Calcifediol; 25-hydroxy Vitamin D3)
|
| PubChem CID |
6434253
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.704
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
688
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@H](CCC(C(C)(C)O)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
|
| InChi Key |
FCKJYANJHNLEEP-SRLFHJKTSA-N
|
| InChi Code |
InChI=1S/C27H44O3/c1-18-8-12-22(28)17-21(18)11-10-20-7-6-16-27(5)23(13-14-24(20)27)19(2)9-15-25(29)26(3,4)30/h10-11,19,22-25,28-30H,1,6-9,12-17H2,2-5H3/b20-10+,21-11-/t19-,22+,23-,24+,25?,27-/m1/s1
|
| Chemical Name |
(6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~120.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4002 mL | 12.0008 mL | 24.0015 mL | |
| 5 mM | 0.4800 mL | 2.4002 mL | 4.8003 mL | |
| 10 mM | 0.2400 mL | 1.2001 mL | 2.4002 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA